Association of musculoskeletal complaints and gliptin use: Review of spontaneous reports

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 10, 2013, Pages 1115-1118

  Tarapués, Mónica ^a   Cereza, Gloria ^a,b,c   Figueras, Albert ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Fundacion Institut Catala de Farmacologia   (Spain)

^c Catalan Centre of Pharmacovigilance   (Spain)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Drug utilization; Pharmacoepidemiology; Pharmacovigilance; Spontaneous reporting system; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PRAVASTATIN; ROSUVASTATIN; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT STIFFNESS; JOINT SWELLING; LIMB PAIN; LONG TERM CARE; MALE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; POLYARTHRITIS; PRIORITY JOURNAL;

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; DRUG UTILIZATION; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; SPONTANEOUS REPORTING SYSTEM; TYPE 2 DIABETES MELLITUS;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MUSCULOSKELETAL DISEASES; RETROSPECTIVE STUDIES;

EID: 84884931773     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3503     Document Type: Article

References (15)

1. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011; 33: 1609-1629.
2. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the world health organization VigiBase. Diabetes Care 2011; 34: 369-374.
3. Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med 2012; 29: 693-694.
4. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008; 25: 1229-1230.
5. Yamauchi K, Sato Y, Yamashita K, et al. RS3PE In association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care 2012; 35: e7-e7.
6. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 2009; 29: 352-356.
7. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11(1): 3-10.
8. European Medicines Agency. Summary of product characteristics Januvia®. Update 24/09/2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf [29 October 2012].
9. Food and Drug Administration. Summary of product characteristics Januvia®. Update 18/10/2012 h http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s025lbl.pdf [29 October 2012].
10. Netherlands Pharmacovigilance Centre Lareb. An overview of reports on sitagliptin.[Internet] 2011. http://www.lareb.nl/LarebCorporateWebsite/media/publicaties/kwb_2011_1_sitag.pdf [1 May 2012].
11. Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005; 166: 433-442.
12. Fletcher MA, Zeng XR, Maher K, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010; 5: e10817. doi: 10.1371/journal.pone.0010817.
13. Gerli R, Muscat C, Bertotto A, et al. CD26 Surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996; 80: 1-7.
14. Guieu R, Fenouillet E, Devaux C, et al. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain Res 2006; 166: 230-235.
15. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009; 49: 483-488.